


Global Myasthenia Gravis Market: Size, Trends & Forecasts (2017-2021)

August 2017



Global Myasthenia Gravis Market

Scope of the Report

The report titled "Global Myasthenia Gravis Market: Size, Trends & Forecasts (2017-2021)" provides a detailed analysis of the myasthenia gravis market with description of market size and growth. The analysis includes market size in terms of value, and market share on the basis of therapy, by cases and by severity.

The report also provides a brief regional analysis of the US. The analysis includes market size in terms of number of patients on the basis of types of myasthenia gravis. Geographically, the Americas were the largest market and is expected to dominate the market in the forecasted period also. The growth in the market is estimated on the back of rising elderly population in the region.

Furthermore, the report also assesses the key opportunities available in the market and outlines the market dynamics that are and will be accountable for growth of the industry. Growth of the global myasthenia gravis market has also been forecasted for the period 2017-2021, taking into consideration previous growth outlines, growth drivers and the existing and forthcoming trends.

Some of the prominent players of the market include Avadel Pharmaceuticals, Hoffmann-La Roche, Pfizer, and Argenx. A brief company profiling of these major players have also been provided in the report on the basis of aspects like business overview, financial overview and business strategies adopted by respective companies.

Global Myasthenia Gravis Market

Company Coverage

Avadel Pharmaceuticals

F. Hoffmann-La Roche

Pfizer

Argenx

Region Coverage

The US

Global Myasthenia Gravis Market

Executive Summary


Myasthenia gravis is a chronic neuromuscular disease that leads to weakness in the skeletal muscles, which help in the breathing and movement of the body parts including the arms and legs. The word 'myasthenia gravis' has Latin and Greek origin and means serious muscle weakness. Myasthenia Gravis is rare and only affects 14 to 20 people out of every 100,000. The main symptom of myasthenia gravis is weakness in the voluntary skeletal muscles, which are muscles under one's control. Weakness associated with MG typically gets worse with more activity and improves with rest.

The disease is categorized into six types namely: Early-Onset MG, Late-Onset MG, Thymoma-Associated MG, MG with Anti-Musk Antibodies, Ocular MG, and MG with no detectable AChR and MuSK Antibodies. Myasthenia gravis is caused by an error in the transmission of nerve impulses to muscles. Major treatments available for MG are Symptomatic Treatment, Rapid Short-Term Immune-Modulating Treatment, Chronic Long-Term Immune-Modulating Treatment and Surgery.

The global myasthenia gravis market has increased over the past few years and projections are made that the market would rise in the forecasted period i.e. 2017 to 2021 at a significant growth rate. The global myasthenia gravis market is expected to boost by the major factors such as rising geriatric population, technological advancements, approval of monoclonal antibodies, strategies such as mergers and acquisitions etc. Yet the market growth is restrain by some challenges such as competition from off-label drugs, limited availability of FDA approved drugs, high cost of the treatment etc.

Global Myasthenia Gravis Market Analysis


Global Myasthenia Gravis Drugs Market by Value; 2016-2021 (US\$ Million)



Global myasthenia gravis drugs market is expected to show upward trends in the forecasted period i.e. 2017 to 2021 on the back of

In 2016, the market was valued at US\$..... million, which is estimated to reach US\$.... million in 2017 with YOY growth rate of approximately%. Over the period spanning from 2017 to 2021, market is projected to grow at a compound annual growth rate of%.


Global Myasthenia Gravis Market by Therapy; 2016



Of total therapies available for the disease, Anticholinesterase inhibitors accounted for largest share in the market with% while other therapies such as Immunosuppressants and Intravenous immune globulins had a share of% and% respectively. Anticholinesterase inhibitors are the most common type of therapy for the disease.


Global Myasthenia Gravis Market Analysis

Global Myasthenia Gravis Market by Cases; 2016



Peripheral muscles are most prone to be affected by MG. The disease has localized to peripheral muscles in% of patients. MG progressed to ocular muscles and bulbar in% and% of patients respectively. Half of the patients has generalized myasthenia gravis.

Global Myasthenia Gravis Cases by Severity; 2016




In myasthenia gravis cases that progressed beyond ocular localization,% and% were of severe and moderate weakness respectively.

.....% of patients had low weakness symptoms. There was no significant gender differences in the severity of weakness, and mortality ranged between% from the disease.


The US Myasthenia Gravis Market Analysis

The US Myasthenia Gravis Market by Total Patient Volume; 2017-2021E (Thousand)



In Americas region, the US had the highest number of patients suffering from the disease. By the end of 2017, the number of patients are expected to reach thousand. A total of thousand population would be affected by the disease by 2021.


The US Myasthenia Gravis Market by 2nd Line Patient Volume; 2017-2021E (Thousand)



In the US, population suffering from MG 2nd line is expected to reach thousand in numbers by the end of 2017. Total number of patients suffering from MG 2nd line is projected to reach thousand by 2021. would be the major cause for growing number of patients.

The US Myasthenia Gravis Market Analysis


The US Myasthenia Gravis Market by 3rd Line Severe Chronic Refractory Patient Volume; 2017-2021E (Thousand)



By the end of 2017, total number of patients expected to affect by disease would bethousand which is estimated to reach thousand by 2021.

Mostly patients developed the disease due to autoimmune disorders or% of patients may have family members with myasthenia gravis.

The US Myasthenia Gravis Market by Crisis Patient Volume; 2017-2021E (Thousand)



Crisis MG is estimated to affect least the US population among the above mentioned types of MG. In 2017, approximately a total number ofthousand is estimated to affect by the disease. The number of patients is expected to reach thousand by 2021. Crisis MG is mostly found in population age betweenyears.